Hovione today announced the expansion of its solutions to solve issues of poor bioavailability, patient acceptability and the enabling of optimal delivery for non-oral routes of administration.

Hovione's toolkit of solutions now includes crystal design, particle size reduction to the micro or nano-scale and amorphous solid dispersions. These services are offered from bench to commercial scale and are complemented with formulation development and clinical manufacture to Phase II.